Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + pemetrexed + sintilimab
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of carboplatin (a platinum-based chemotherapy agent), pemetrexed (an antifolate chemotherapy drug), and sintilimab (an anti-PD-1 monoclonal antibody). This regimen is primarily used for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). The combination works through multiple mechanisms: carboplatin forms DNA crosslinks disrupting cancer cell division, pemetrexed inhibits folate-dependent enzymes required for DNA synthesis, and sintilimab blocks the PD-1 pathway to restore anti-tumor immune response.
- Other names
- sintilimab plus pemetrexed and carboplatinsintilimab-pemetrexed-carboplatinimmunochemotherapy-Jianxing He-non-small cell lung cancer
02
Targets
TS (Thymidylate synthase)SHMT2 (Serine hydroxymethyltransferase 2)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)DNAGART (GAR transformylase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on carboplatin + pemetrexed + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + pemetrexed + sintilimab.